Annual report pursuant to Section 13 and 15(d)

Collaboration and License Agreements (Details)

v3.19.3.a.u2
Collaboration and License Agreements (Details) - USD ($)
12 Months Ended
Feb. 05, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2003
Other income     $ 368,750  
Upfront payment   $ 3,000,000    
Revenue recognized   0    
Deferred revenue   1,500,000    
Amount due   1,500,000    
Fixed consideration   3,000,000    
RX-3117 License [Member]        
Upfront payment   2,500,000    
RX-3117 Clinical Material [Member]        
Upfront payment   $ 500,000    
RX-0201 [Member]        
Other income $ 368,750      
Research and development period   20 years    
Reduction of research and development expenses     $ 6,250  
Research and development arrangement, one-time fee       $ 1,500,000
Percentage of licensing revenue 50.00%      
Licensing revenue agreement $ 5,000,000      
China [Member]        
Milestone payment   $ 126,000,000    
Republic of Singapore, China, Hong Kong, Macau and Taiwan [Member]        
Milestone payment   $ 100,000,000